SHANGHAI YIZHONG(SH:688091)2023-10-29 16:00Financial Performance - Shanghai Yizhong achieved operating revenue of CNY 279,201,375.63 for the first three quarters of 2023, an increase of CNY 112,877,921.73, representing a year-on-year growth of 67.87%[4] - The net profit attributable to shareholders for the first three quarters was CNY 130,623,890.97, up by CNY 26,457,559.68, reflecting a year-on-year increase of 25.40%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached CNY 112,586,412.39, which is an increase of CNY 30,617,713.64, marking a year-on-year growth of 37.35%[4] - Total operating revenue for the first three quarters of 2023 reached ¥279,201,375.63, a significant increase from ¥166,323,453.90 in the same period of 2022, representing a growth of approximately 67.8%[20] - Net profit for the first three quarters of 2023 was ¥130,623,890.97, up from ¥104,166,331.29 in 2022, reflecting a growth of approximately 25.4%[21] - The total profit for the first three quarters of 2023 was ¥151,275,900.92, compared to ¥103,248,920.62 in 2022, reflecting an increase of approximately 46.5%[21] Research and Development - Research and development expenses totaled CNY 16,707,263.59 for the first three quarters, representing a year-on-year increase of 251.84%[5] - The ratio of R&D expenses to operating revenue was 9.80%, an increase of 7.46 percentage points compared to the previous year[5] - Research and development expenses for the first three quarters of 2023 were ¥16,707,263.59, compared to ¥4,748,526.47 in 2022, indicating a substantial increase of about 252.5%[20] Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 1,516,346,470.11, reflecting an increase of 11.94% from the end of the previous year[5] - The equity attributable to shareholders of the listed company was CNY 1,427,298,910.82, which is an increase of 8.20% compared to the end of the previous year[5] - The company's total liabilities as of the end of the third quarter of 2023 amounted to ¥89,047,559.29, compared to ¥35,415,374.82 in the previous year, showing an increase of about 151.2%[22] - The total equity attributable to shareholders reached ¥1,427,298,910.82, up from ¥1,319,178,266.25, marking an increase of approximately 8.2%[22] - The total liabilities included accounts payable of ¥26,620,656.86, which increased from ¥21,534,488.09, showing a growth of about 23%[17] Cash Flow - The cash flow from operating activities for the first three quarters was CNY 62,726,942.85, down by 36.75% year-on-year[5] - Net cash flow from operating activities was 62,726,942.85, a decrease of 36.8% compared to 99,165,596.06 in the previous period[24] - Total cash inflow from investment activities was 1,069,893,593.22, down 57.6% from 2,525,653,629.81 in the previous period[25] - Net cash flow from investment activities was 53,719,564.68, a significant decrease from 489,310,279.81 in the previous period[25] - Cash outflow for employee payments was 38,902,665.37, an increase of 116.5% from 17,961,631.93 in the previous period[24] - Cash outflow for taxes paid was 28,019,544.53, a significant increase from 1,235,629.27 in the previous period[24] - Net cash flow from financing activities was -23,281,275.34, compared to -16,889,538.47 in the previous period, indicating a worsening cash position[25] Shareholder Information - The company has a total of 19,002,728 shares held by Shanghai Kaibao Pharmaceutical Co., Ltd., representing 12.01% of total shares[13] - The top ten shareholders include significant holdings by individuals and entities, with the largest being Zhou Jinsong at 19.50%[12] Market and Product Development - The company reported a significant increase in core product sales, which contributed to the overall revenue growth[10] - The company is focused on expanding its market presence and developing new products, although specific details on new technologies were not disclosed in the report[15]